PURPOSE: The purpose of this work was to evaluate the usefulness of perfusion CT in the evaluation of patients with chronic cerebral ischemia by comparing it with xenon CT (Xe-CT). METHOD: Cerebral blood flow (CBF) of perfusion CT (CBFper) and time to peak (TTP) were compared with the CBF of Xe-CT (CBFxe) in 18 patients. Cerebral blood volume (CBV) was compared with cerebral vascular reserve (CVR) in 10 of 18 patients who underwent pre- and postacetazolamide Xe-CT. RESULTS: CBFper and TTP demonstrated a high correlation with CBFxe in relative values by side-to-side comparisons (r = 0.743, p < 0.0001 and r = -0.760, p < 0.0001, respectively). There was a negative correlation between relative CBV and relative CVR (r = -0.637, p = 0.0025). Visually, territories with delayed TTP corresponded well to those of decreased CBFxe, but these territories tended to be larger in TTP maps. CONCLUSION: Perfusion CT is a useful tool to evaluate chronic hemodynamic disturbance and can be an alternative method for those using acetazolamide challenge.
PURPOSE: The purpose of this work was to evaluate the usefulness of perfusion CT in the evaluation of patients with chronic cerebral ischemia by comparing it with xenon CT (Xe-CT). METHOD: Cerebral blood flow (CBF) of perfusion CT (CBFper) and time to peak (TTP) were compared with the CBF of Xe-CT (CBFxe) in 18 patients. Cerebral blood volume (CBV) was compared with cerebral vascular reserve (CVR) in 10 of 18 patients who underwent pre- and postacetazolamide Xe-CT. RESULTS: CBFper and TTP demonstrated a high correlation with CBFxe in relative values by side-to-side comparisons (r = 0.743, p < 0.0001 and r = -0.760, p < 0.0001, respectively). There was a negative correlation between relative CBV and relative CVR (r = -0.637, p = 0.0025). Visually, territories with delayed TTP corresponded well to those of decreased CBFxe, but these territories tended to be larger in TTP maps. CONCLUSION: Perfusion CT is a useful tool to evaluate chronic hemodynamic disturbance and can be an alternative method for those using acetazolamide challenge.
Authors: M Matsumoto; N Kodama; Y Endo; J Sakuma; Ky Suzuki; T Sasaki; K Murakami; Ke Suzuki; T Katakura; F Shishido Journal: AJNR Am J Neuroradiol Date: 2007-02 Impact factor: 3.825
Authors: James D Eastwood; Michael H Lev; Max Wintermark; Clemens Fitzek; Daniel P Barboriak; David M Delong; Ting-Yim Lee; Tarek Azhari; Michael Herzau; Vani R Chilukuri; James M Provenzale Journal: AJNR Am J Neuroradiol Date: 2003-10 Impact factor: 3.825
Authors: A Waaijer; I C van der Schaaf; B K Velthuis; M Quist; M J P van Osch; E P A Vonken; M S van Leeuwen; M Prokop Journal: AJNR Am J Neuroradiol Date: 2007-05 Impact factor: 3.825
Authors: Max Wintermark; Wade S Smith; Nerissa U Ko; Marcel Quist; Pierre Schnyder; William P Dillon Journal: AJNR Am J Neuroradiol Date: 2004-05 Impact factor: 3.825